34
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy.

          Related collections

          Most cited references6

          • Record: found
          • Abstract: not found
          • Article: not found

          2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering

              Effects on specific fatal and nonfatal end points appear to vary for low-density lipoprotein cholesterol (LDL-C)-lowering drug trials.
                Bookmark

                Author and article information

                Journal
                New England Journal of Medicine
                N Engl J Med
                New England Journal of Medicine (NEJM/MMS)
                0028-4793
                1533-4406
                November 07 2018
                November 07 2018
                Affiliations
                [1 ]From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
                Article
                10.1056/NEJMoa1801174
                30403574
                88b78eba-ce06-491f-aaaf-fe5f5b07e0df
                © 2018

                http://www.nejmgroup.org/legal/terms-of-use.htm

                History

                Comments

                Comment on this article